A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

NCT06466395 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Refractory Acute Leukemia
Relapsed Acute Leukemia
Undifferentiated Leukemia
Bi-Phenotypic Leukemia

Interventions

DRUG: Venetoclax
DRUG: Hyper-CVAD

Sponsor

M.D. Anderson Cancer Center